Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously

This study has been completed.
DynPort Vaccine Company LLC, A CSC Company
Information provided by (Responsible Party):
Baxalta US Inc. Identifier:
First received: June 1, 2006
Last updated: June 26, 2015
Last verified: April 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2008
  Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)